转移性结直肠癌一线Ⅲ期试验患者特征与分层因素报告的系统评价
结果显示,各试验报告48种患者特征和29种分层因素,2007年提出的标准化建议未显著提高报告一致性,持续存在异质性。
要点
- 各试验报告患者特征中位数为9种(范围5-18),共涉及48种特征。
- 体能状态与治疗中心是最常用分层因素,使用率均超过60%。
- 发表年份与对2007年建议的依从性之间无显著相关性。
核心结论
- 一线转移性结直肠癌Ⅲ期试验在患者特征报告与分层因素使用上持续存在异质性,2007年建议未提高报告一致性。
主要发现
- 共报告48种患者特征,每项研究中位报告9种(范围5-18)。
- 年龄、性别、体能状态、原发肿瘤部位与辅助化疗报告率较高(87%-100%)。
- 碱性磷酸酶、乳酸脱氢酶与白细胞计数等实验室指标报告率较低(10%-25%)。
- 共识别29种分层因素,每项研究中位使用3种(范围1-9)。
- 体能状态与治疗中心是最常见分层因素,使用率均超过60%。
关键数值与推荐
- 2007年建议的12项参数中,每项研究中位报告8项(范围4-11)。
- 发表年份与对2007年建议的依从性之间无显著相关性。
临床怎么用
- 解读一线转移性结直肠癌Ⅲ期试验结果时,需注意患者特征与分层因素报告的异质性,跨研究比较与外推需谨慎。
局限性
- 检索截止于2016年6月,仅纳入一线Ⅲ期试验,未评估其他分期或治疗线数的试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patient characteristics and stratification factors are important factors influencing trial outcomes. Uniform reporting on these parameters would facilitate cross-study comparisons and extrapolation of trial results to clinical practice. In 2007, standardisation on patient characteristics reporting and stratification in metastatic colorectal cancer (mCRC) trials was proposed. We investigated the reporting of prognostic factors and implementation of this proposal in mCRC trials published from 2005 to 2016. METHODS: We searched PubMed and Embase (January 2005 - June 2016) for first-line phase 3 mCRC trials. Patient characteristics reporting and use of stratification factors were extracted and analysed for adherence to the proposal from 2007. RESULTS: Sixty-seven trials (35,315 patients) were identified, reporting 48 different patient characteristics (median: 9 [range: 5-18] per study). Age, gender, performance status (PS), primary tumour site and adjuvant chemotherapy were frequently reported (87%-100%), in contrast to laboratory values, such as alkaline phosphatase, lactate dehydrogenase and white blood cell count (10%-25%). We identified 29 different stratification factors (median: 3 [range: 1-9] per study). The most common strata were PS and treatment centre (>60%). A median of 8/12 (range: 4-11) of the proposed parameters was reported. Although the percentage of studies reporting each factor slightly increased over time, there was no significant correlation between publication year and adherence to the proposal from 2007. CONCLUSIONS: We observed persistent heterogeneity in the reporting of patient characteristics and use of stratification factors in first-line mCRC trials. The proposal from 2007 has not led to increased uniformity of patient characteristics reporting and use of stratification over time. There is an urgent need to address this issue to improve the interpretation of trial results.
引用
- Goey KKH, Mahmoud R, Sørbye H, et al. Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. Eur J Cancer. 2018. PMID: 29729562. doi:10.1016/j.ejca.2018.03.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。